mProX™ Human FLT3 Stable Cell Line

Product Information

Target Protein

FLT3

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

AML; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Leukemia, Acute Myeloid and Acute Myeloblastic Leukemia Without Maturation. Among its related pathways are sorafenib-resistant FLT3 mutants and GPCR Pathway

Gene ID

2322

UniProt ID

P36888

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Fms-like tyrosine kinase 3 (FLT3), a member of the receptor tyrosine kinase (RTK) protein family, is encoded by the FLT3 gene. A process known as signal transduction is used by receptor tyrosine kinases to transfer messages from the cell surface within the cell. Certain cell types include the FLT3 protein on their outer membrane, where it can attach to a particular protein known as FLT3 ligand, or FL. The FLT3 protein is activated by this interaction, and this in turn activates a number of intracellular proteins that are involved in several signaling cascades. The FLT3 protein stimulates signaling pathways that regulate numerous critical physiological functions, including cell growth, division, and survival, especially those of hematopoietic progenitor cells, which are precursors to blood cells. The customized FLT3 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Deborah

This FLT3 cell line enabled us to conduct our experiments with confidence, and we achieved publication-worthy data. Sep 19 2021

chat Verified Customer

chat James

The FLT3 cell line demonstrated remarkable specificity and sensitivity, which helped us unravel complex signaling pathways. Mar 18 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 FLT3-ITD expressing AML patient samples and cell lines express the NOX4D 28 kDa isoform.

The FLT3-ITD expressing AML cell line, MV4-11, and 32D cells transfected with FLT3-WT or FLT3-ITD were used for subcellular fractionation. By using western blot analysis, the expression of NOX4 67 kDa, NOX4D 28 kDa, and p22 phox was evaluated.

Ref: Moloney, Jennifer N., et al. "Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML." Oncotarget 8.62 (2017): 105440.

Pubmed: 29285262

DOI: 10.18632/oncotarget.22241

Research Highlights

This review focuses on the clinical classification of AML, the pathological and prognostic significance of FLT3 mutations, the latest developments with next-generation FLT3 inhibitors, and the mechanisms of resistance to FLT3 inhibitors.
Daver, Naval, et al. "Targeting FLT3 mutations in AML: review of current knowledge and evidence." Leukemia 33.2 (2019): 299-312.
Pubmed: 30651634 DOI: 10.1038/s41375-018-0357-9

About one-third of individuals with acute myeloid leukemia (AML) have a mutation in the FMS-like tyrosine kinase 3 (FLT3) gene. These mutations can be internal tandem duplications (FLT3-ITD) or point mutations that primarily affect the tyrosine kinase domain (FLT3-TKD).
Antar, Ahmad I., et al. "FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions." Leukemia 34.3 (2020): 682-696.
Pubmed: 31919472 DOI: 10.1038/s41375-019-0694-3